Cannabis Use Disorder (CUD) - Pipeline Insight, 2025

This “Cannabis Use Disorder (CUD) - Pipeline Insight, 2025” report provides comprehensive insights about 5+ companies and 5+ pipeline drugs in Cannabis Use Disorder (CUD) pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Cannabis Use Disorder (CUD): Understanding

Cannabis Use Disorder (CUD): Overview

Cannabis, known colloquially as marijuana, ranks as the third most utilized psychoactive substance globally, trailing only alcohol and nicotine. Its consumption methods vary from traditional smoking and vaping to more modern approaches like dabbing and ingesting via edibles, beverages, and tinctures. Additionally, topical creams infused with cannabis compounds offer localized relief for various ailments. This diverse range of consumption methods reflects the widespread popularity and versatility of cannabis within contemporary society. Symptoms occurring within a 12-month period include continuing to use cannabis despite physical or psychological problems, social or relationship problems, or knowledge of having a persistent or recurrent physical or psychological problem. Withdrawal symptoms can also occur when discontinuing cannabis, such as dysphoria, anxiety, irritability, depression, restlessness, disturbed sleep, gastrointestinal symptoms, and decreased appetite.

Prolonged and heavy cannabis use exerts pathophysiological effects on the brain by altering its circuitry, primarily through the action of THC, the main psychoactive compound in marijuana. While the specific mechanisms remain unclear, THC's interaction with cannabinoid receptors CB1 and CB2 modulates various neurotransmitter systems, including endocannabinoids, gamma-aminobutyric acid, glutamate, and serotonin. This modulation influences processes such as pain perception, mood regulation, appetite, nausea, and sexual activity. Furthermore, cannabis impacts the striatal dopamine system, albeit with insufficient evidence to conclusively implicate dopamine receptors in addiction. Heavy cannabis use also modifies conscious experience by affecting self-awareness, motivation, and memory function, often resulting in reduced anxiety and altered personal experience.

Laboratory testing of urine, blood, saliva, or hair can be useful to detect cannabis use, but results should be considered along with a clinical rationale. Assays typically rely on the detection of the most common active metabolite, delta-9-tetrahydrocannibinolic acid. It has been studied thoroughly, and this abundant acid metabolite has become an established urinary marker of cannabis consumption in forensic, clinical, and environmental analyses. There are a couple of different treatment options for people with cannabis use disorder. Several types of counseling or therapy have been found beneficial for reducing cannabis use and the subsequent problems this drug creates. They are: Cognitive Behavioral Therapy, Motivational Enhancement Therapy, Contingency Management.

'Cannabis Use Disorder (CUD) - Pipeline Insight, 2025' report outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Cannabis Use Disorder (CUD) pipeline landscape is provided which includes the disease overview and Cannabis Use Disorder (CUD) treatment guidelines. The assessment part of the report embraces, in depth Cannabis Use Disorder (CUD) commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Cannabis Use Disorder (CUD) collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Report Highlights

The companies and academics are working to assess challenges and seek opportunities that could influence Cannabis Use Disorder (CUD) R&D. The therapies under development are focused on novel approaches to treat/improve Cannabis Use Disorder (CUD).

Cannabis Use Disorder (CUD) Emerging Drugs Chapters

This segment of the Cannabis Use Disorder (CUD) report encloses its detailed analysis of various drugs in different stages of clinical development, including Phase III, II, I, Preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Cannabis Use Disorder (CUD) Emerging Drugs

AEF0117: Aelis Farma

AEF0117 is the first drug candidate of the new pharmacological class of CB1-SSi, a rationally designed analog of pregnenolone, the naturally occurring steroid hormone that binds to a specific site on the CB1 receptor. Pregnenolone and AEF0117 do not modify the binding of agonists to the CB1 but only block certain signaling pathways activated by cannabinoid agonists, such as THC, on the CB1. Through this selective mechanism of action, AEF0117 potently inhibits THC's behavioral effects without altering normal behavior. Unlike pregnenolone, AEF0117, is highly bioavailable when taken orally, exhibits favorable pharmacokinetic properties for once-daily administration, and is not converted into other steroids. Currently, the drug is in Phase II stage of its clinical trial for the treatment of cannabis use disorder.

Cannabis Use Disorder (CUD): Therapeutic Assessment

This segment of the report provides insights about the different Cannabis Use Disorder (CUD) drugs segregated based on following parameters that define the scope of the report, such as:

Major Players in Cannabis Use Disorder (CUD)

• There are approx. 5+ key companies which are developing the therapies for Cannabis Use Disorder (CUD). The companies which have their Cannabis Use Disorder (CUD) drug candidates in the most advanced stage, i.e. Phase II include, Aelis Farma.

Phases

The report covers around 5+ products under different phases of clinical development like

• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates

Route of Administration

Cannabis Use Disorder (CUD) pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Oral
• Intravenous
• Subcutaneous
• Parenteral
• Topical

Molecule Type

Products have been categorized under various Molecule types such as

• Recombinant fusion proteins
• Small molecule
• Monoclonal antibody
• Peptide
• Polymer
• Gene therapy

Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Cannabis Use Disorder (CUD): Pipeline Development Activities

The report provides insights into different therapeutic candidates in Phase III, II, I, preclinical and discovery stage. It also analyses Cannabis Use Disorder (CUD) therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Cannabis Use Disorder (CUD) drugs.

Cannabis Use Disorder (CUD) Report Insights

• Cannabis Use Disorder (CUD) Pipeline Analysis
• Therapeutic Assessment
• Unmet Needs
• Impact of Drugs

Cannabis Use Disorder (CUD) Report Assessment

• Pipeline Product Profiles
• Therapeutic Assessment
• Pipeline Assessment
• Inactive drugs assessment
• Unmet Needs

Key Questions

Current Treatment Scenario and Emerging Therapies:

• How many companies are developing Cannabis Use Disorder (CUD) drugs?
• How many Cannabis Use Disorder (CUD) drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Cannabis Use Disorder (CUD)?
• What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Cannabis Use Disorder (CUD) therapeutics?
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for Cannabis Use Disorder (CUD) and their status?
• What are the key designations that have been granted to the emerging drugs?

Key Players

• Aelis Farma
• Anebulo Pharmaceuticals
• Indivior

Key Products

• AEF0117
• ANEB-001
• INDV-5004

This product will be delivered within 2 business days.